Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS3-007A in healthy adults
NCT05611281Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in growth hormone deficiency (GHD) comparing GS3-007 oral liquid with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started Sep 2022; status: completed.
02
Drugs
GS3-007
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT05611281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611281.